Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Trends in Endocrinology & Metabolism · 2026
DOI: 10.1016/j.tem.2025.06.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2026. Verfasst von Ruth Frampton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Diabetes and Metabolism, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; St Vincent's Healthcare Clinical Ca…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Incretins, Cardiovascular Diseases. Die Arbeit nennt 91 Literaturangaben. Gefördert von: University of New South Wales, Medical Research Future Fund, Juvenile Diabetes Research Foundation Australia.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Diabetes and Metabolism, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; St Vincent's Healthcare Clinical Campus, School of Clinical Medicine, University of New South Wales Medic…
- Boden Initiative, Charles Perkins Centre, The University of Sydney, NSW, Australia; Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Endocr…
Förderung
- University of New South Wales
- Medical Research Future Fund
- Juvenile Diabetes Research Foundation Australia
Zitieren
APA
Frampton, R., Hocking, S., Snaith, J. R., & Greenfield, J. R. (2026). Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2025.06.004
Vancouver
Frampton R, Hocking S, Snaith JR, Greenfield JR. Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends in Endocrinology & Metabolism. 2026. doi:10.1016/j.tem.2025.06.004
BibTeX
@article{Frampton2026,
author = {Frampton, Ruth and Hocking, Samantha and Snaith, Jennifer R and Greenfield, Jerry R},
title = {Targeting cardiometabolic risk in type 1 diabetes through incretin physiology},
journal = {Trends in Endocrinology & Metabolism},
year = {2026},
doi = {10.1016/j.tem.2025.06.004}
}
EUVIMED